Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 83%
In fiscal 2025, Niagen Bioscience, Inc. reported revenue of $129M, up 29.9% year over year. Operating margin was 12.6% and net margin 13.4%, on a free-cash-flow margin of n/a with capital expenditure at n/a of revenue. Every figure is computed directly from NAGE's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $129M | 12.6% | 13.4% |
| FY2024 | $100M | 7.8% | 8.6% |
| FY2023 | $84M | -6.7% | -5.9% |
| FY2022 | $72M | -25.9% | -23.0% |
| FY2021 | $67M | -40.1% | -40.2% |
How does NAGE compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.